Ignatiev Introduction Back in June 2023, we wrote a piece on Axcelis Technologies (NASDAQ:ACLS), a specialist in ion implantation technology, when it was flourishing at around lifetime highs. Whilst we appreciated some facets of the business (and still do), we were less certain of its ability to generate ample alpha at those lofty levels, and hence went with a HOLD rating back then. Since then, the stock has given up over 30% of its value, and whilst some risks still remain, we are now prepared to be more b ...